Beijing Shenogen Pharma Group

Beijing Shenogen Pharma Group is a China-based biopharmaceutical company dedicated to the development of first-in-class oncology therapeutics. The company is best known for its research into the Estrogen receptor alpha 36 (ER-alpha36) signaling pathway, which plays a critical role in the development of several cancers. Its lead product, Icaritin (SNG162), is a small molecule derived from traditional Chinese medicine that was approved by the NMPA in 2022 for the treatment of advanced hepatocellular carcinoma. Beyond Icaritin, Shenogen is advancing a diverse pipeline that includes STAT3 inhibitors, oncolytic viruses, and peptide-drug conjugates. The company maintains integrated capabilities spanning drug discovery, clinical development, and GMP-compliant manufacturing. Shenogen aims to address significant unmet medical needs in the global oncology market through innovative drug design and strategic partnerships.